Seelos Therapeutics (NASDAQ:SEEL) is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders and rare diseases. The firm’s strategy centers on identifying and advancing novel small molecules and repurposed drugs that address significant unmet medical needs. With a lead pipeline targeting conditions such as major depressive disorder with suicidal ideation, Parkinson’s disease psychosis and post-traumatic stress disorder, Seelos aims to leverage both innovative chemistry and existing regulatory pathways to accelerate clinical development.
The company’s current product candidates include SLS-002, a psilocybin-based vapor delivery system being evaluated for rapid reduction of suicidal ideation in patients with treatment-resistant depression. In parallel, Seelos is investigating SLS-005, a formulation of the FDA-approved compound pimavanserin for Parkinson’s disease psychosis, and SLS-004, an oral LSD derivative designed for treatment-resistant and chronic psychiatric conditions. These programs are supported by ongoing Phase 1 and Phase 2 clinical trials in the United States, with Seelos engaging closely with the U.S. Food and Drug Administration to define regulatory pathways and expedite development timelines.
Founded in 2014 and headquartered in Dallas, Texas, Seelos Therapeutics was established by a team of scientists and industry veterans with deep expertise in neuropharmacology and drug development. Under the leadership of Chief Executive Officer Frank J. Farrell and Chief Medical Officer Arun Chopra, the company has built a multidisciplinary organization encompassing clinical research, regulatory affairs and manufacturing. Seelos maintains its research and development activities in multiple U.S. locations, collaborating with contract research organizations and academic partners to support its clinical trial network.
Seelos is committed to advancing treatments that can transform the standard of care for CNS disorders and rare conditions. By focusing on both novel compounds and strategic drug repurposing, the company seeks to reduce the time and cost of bringing therapies to patients. Looking ahead, Seelos plans to expand its clinical pipeline, explore international development opportunities and pursue partnerships that enhance its capacity to address critical neurological and psychiatric diseases.
